Abstract S89 Table 1

Comparison of different indices at baseline and after treatment between the two groups. Data expressed as medians and ranges

Markers	Placebo		Fluticasone Propionate

Comparison	Before	After	Before	After

% Rbm fragmentation	24(6–100)^*	26(2–48)	19(0.2–42)	2(0–88) ^†!^
S100A4 positive cells in basal epithelium (BE) per mm of Rbm	19(2–31)^*	17(10–35)	25(2–55)	12(0.6–24) ^†!
S100A4 positive cells in Rbm per mm of Rbm	23(14–82)^*	29(3–48)	44(15–92)	20(2–60) ^†!
MMP-9 positive cells in Rbm clefts per mm of Rbm	11(0–41)^*	13(0–27)	5(0–43)	0(0–6)^†^
EGFR % in the epithelium	14(3–38)^*	10(1–39)	34(14–59)	5(2–43) ^†!^

↵* No significant difference at baseline between placebo/ICS groups, but all significantly different to normal controls at baseline (p<0.007).
Significant differences: † Change within ICS group (p<0.003); !changes over time with ICS compared to those on placebo for Rbm fragmentation (p<0.04); S100A4 in BE (p<0.009) and Rbm (p<0.002); EGFR (p<0.02).
↵ No significant difference after the treatment compared to normal controls.